<DOC>
	<DOC>NCT01879020</DOC>
	<brief_summary>The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of TA-8995 after multiple doses in healthy adult male subjects</brief_summary>
	<brief_title>Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Free from any clinically significant illness or disease as determined by their medical history, physical examination, laboratory and other tests and as judged by the Investigator. Between 18 55 years old. Male of Caucasian ethnic origin. Body mass index (BMI) in the range of 19 33 kg/m² and had a minimum weight of 50 kg. Subjects with a BMI in the range 30.0 33.0 kg/m² had to have a waist measurement of ≤ 91 cm. High density lipoprotein (HDL)C level of greater or equal to 2.59 mmol/L (≥ 100 mg/dL) at Screening. Abnormal Electrocardiogram (ECG) at Screening or Day 1 including a QTc ≥ 430 ms (The QTcinterval was calculated automatically according to Bazett's formula. In the case of results of ≥ 430 ms, QTc was additionally calculated manually using Fridericia's formula which was used as an exclusion criterion). Family history of long QT syndrome, hypokalaemia or Torsades de Pointes Impaired endocrine, thyroid, hepatic, respiratory or renal function, diabetes mellitus, coronary heart disease or history of any psychotic illness Presence or history of gastrointestinal, hepatic or renal disease or any other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>MT-8995</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Cholesteryl ester transfer proteins</keyword>
</DOC>